{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:24:02Z","timestamp":1789773842205,"version":"4.0.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010425","name":"Tri-Service General Hospital","doi-asserted-by":"publisher","award":["TSGH-D-113083"],"award-info":[{"award-number":["TSGH-D-113083"]}],"id":[{"id":"10.13039\/501100010425","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lymphopenia is a frequent complication of pelvic radiotherapy and may impair systemic immune surveillance. This study aimed to evaluate the prognostic impact of acute severe lymphopenia (ASL) in rectal cancer and to identify dosimetric predictors relevant to immune-sparing radiotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with non-metastatic rectal cancer treated with radiotherapy between 2018 and 2022 were retrospectively reviewed. Clinical variables, serum biomarkers (CEA and NLR), lymphocyte counts, and pelvic bone marrow dosimetry were analyzed. Associations between ASL, distant metastasis-free survival (DMFS), overall survival (OS), and dosimetric metrics were assessed using multivariable models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 161 patients were included, with 69.6% developing ASL. Patients with ASL had inferior 3-year DMFS (72.6% vs. 84.7%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.034), and ASL remained an independent predictor of poorer DMFS (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.027). ECOG performance status\u2009\u2265\u20091 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005), clinical N2 stage (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.016), and baseline CEA\u2009&gt;\u20095 ng\/mL (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.041) were also associated with worse DMFS, while adjuvant chemotherapy was protective (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Predictors of ASL included lower baseline absolute lymphocyte count (OR 0.87, 95% CI 0.81\u20130.93 per 0.1\u2009\u00d7\u200910\u2079\/L increase;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), higher clinical T stage (OR 2.38, 95% CI 1.01\u20135.56;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.046), and greater low-dose irradiation to the lower pelvis\u2014V5 (OR 1.06, 95% CI 1.02\u20131.11 per 1% increase;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005), for which the optimal predictive cut-off was 88%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ASL was associated with increased risk of distant metastasis. As baseline immunity and disease burden are non-modifiable, minimizing lower pelvic V5 using as low as reasonably achievable (ALARA)\u2013based planning constraints may help reduce ASL risk and support immune-sparing radiotherapy in rectal cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13014-026-02791-3","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T16:16:17Z","timestamp":1769703377000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Radiation-induced severe lymphopenia predicts distant metastasis in rectal cancer: dosimetric implications for immune-sparing radiotherapy"],"prefix":"10.1186","volume":"21","author":[{"given":"Yi-Chiao","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Yen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Chien","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Mei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meei-Shyuan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen-Fu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Cheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chou","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Hsiang","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"2791_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"2791_CR2","doi-asserted-by":"publisher","first-page":"3703","DOI":"10.1002\/cncr.25943","volume":"117","author":"JH Park","year":"2011","unstructured":"Park JH, Yoon SM, Yu CS, Kim JH, Kim TW, Kim JC. Randomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced rectal cancer. Cancer. 2011;117:3703\u201312.","journal-title":"Cancer"},{"key":"2791_CR3","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1200\/JCO.2011.40.1836","volume":"30","author":"R Sauer","year":"2012","unstructured":"Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO\/ARO\/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30:1926\u201333.","journal-title":"J Clin Oncol"},{"key":"2791_CR4","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","volume":"22","author":"T Conroy","year":"2021","unstructured":"Conroy T, Bosset JF, Etienne PL, Rio E, Fran\u00e7ois \u00c9, Mesgouez-Nebout N, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:702\u201315.","journal-title":"Lancet Oncol"},{"key":"2791_CR5","doi-asserted-by":"publisher","first-page":"e766","DOI":"10.1097\/SLA.0000000000005799","volume":"278","author":"EA Dijkstra","year":"2023","unstructured":"Dijkstra EA, Nilsson PJ, Hospers GAP, Bahadoer RR, Meershoek-Klein Kranenbarg E, Roodvoets AGH, et al. Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: A 5-year follow-up of the RAPIDO trial. Ann Surg. 2023;278:e766\u201372.","journal-title":"Ann Surg"},{"key":"2791_CR6","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1200\/JCO.21.01667","volume":"40","author":"J Jin","year":"2022","unstructured":"Jin J, Tang Y, Hu C, Jiang LM, Jiang J, Li N, et al. Multicenter, Randomized, phase III trial of Short-Term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR). J Clin Oncol. 2022;40:1681\u201392.","journal-title":"J Clin Oncol"},{"key":"2791_CR7","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1093\/annonc\/mdv223","volume":"26","author":"C Fernandez-Martos","year":"2015","unstructured":"Fernandez-Martos C, Garcia-Albeniz X, Pericay C, Maurel J, Aparicio J, Montagut C, et al. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trialdagger. Ann Oncol. 2015;26:1722\u20138.","journal-title":"Ann Oncol"},{"key":"2791_CR8","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3109\/07357907.2012.762780","volume":"31","author":"S Yovino","year":"2013","unstructured":"Yovino S, Kleinberg L, Grossman SA, Narayanan M, Ford E. The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to Circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells. Cancer Invest. 2013;31:140\u20134.","journal-title":"Cancer Invest"},{"key":"2791_CR9","doi-asserted-by":"publisher","first-page":"224","DOI":"10.2307\/3577549","volume":"123","author":"N Nakamura","year":"1990","unstructured":"Nakamura N, Kusunoki Y, Akiyama M. Radiosensitivity of CD4 or CD8 positive human T-lymphocytes by an in vitro colony formation assay. Radiat Res. 1990;123:224\u20137.","journal-title":"Radiat Res"},{"key":"2791_CR10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.critrevonc.2018.01.003","volume":"123","author":"BP Venkatesulu","year":"2018","unstructured":"Venkatesulu BP, Mallick S, Lin SH, Krishnan S. A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors. Crit Rev Oncol Hematol. 2018;123:42\u201351.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2791_CR11","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.ijrobp.2019.07.013","volume":"105","author":"C Terrones-Campos","year":"2019","unstructured":"Terrones-Campos C, Ledergerber B, Vogelius IR, Specht L, Helleberg M, Lundgren J. Lymphocyte count Kinetics, factors associated with the End-of-Radiation-Therapy lymphocyte count, and risk of infection in patients with solid malignant tumors treated with Curative-Intent radiation therapy. Int J Radiat Oncol Biol Phys. 2019;105:812\u201323.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2791_CR12","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.ijrobp.2015.04.005","volume":"92","author":"J Huang","year":"2015","unstructured":"Huang J, DeWees TA, Badiyan SN, Speirs CK, Mullen DF, Fergus S, et al. Clinical and dosimetric predictors of acute severe lymphopenia during radiation therapy and concurrent Temozolomide for High-Grade glioma. Int J Radiat Oncol Biol Phys. 2015;92:1000\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2791_CR13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ijrobp.2018.01.069","volume":"101","author":"S Rudra","year":"2018","unstructured":"Rudra S, Hui C, Rao YJ, Samson P, Lin AJ, Chang X, et al. Effect of radiation treatment volume reduction on lymphopenia in patients receiving chemoradiotherapy for glioblastoma. Int J Radiat Oncol Biol Phys. 2018;101:217\u201325.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2791_CR14","doi-asserted-by":"publisher","first-page":"997","DOI":"10.3389\/fonc.2020.00997","volume":"10","author":"X Wang","year":"2020","unstructured":"Wang X, Zhao Z, Wang P, Geng X, Zhu L, Li M. Low lymphocyte count is associated with radiotherapy parameters and affects the outcomes of esophageal squamous cell carcinoma patients. Front Oncol. 2020;10:997.","journal-title":"Front Oncol"},{"key":"2791_CR15","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.ijrobp.2014.04.025","volume":"89","author":"C Tang","year":"2014","unstructured":"Tang C, Liao Z, Gomez D, Levy L, Zhuang Y, Gebremichael RA, et al. Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes. Int J Radiat Oncol Biol Phys. 2014;89:1084\u201391.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2791_CR16","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.6004\/jnccn.2015.0151","volume":"13","author":"SA Grossman","year":"2015","unstructured":"Grossman SA, Ellsworth S, Campian J, Wild AT, Herman JM, Laheru D, et al. Survival in patients with severe lymphopenia following treatment with radiation and chemotherapy for newly diagnosed solid tumors. J Natl Compr Canc Netw. 2015;13:1225\u201331.","journal-title":"J Natl Compr Canc Netw"},{"key":"2791_CR17","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13014-019-1287-z","volume":"14","author":"Q Zhao","year":"2019","unstructured":"Zhao Q, Chen G, Ye L, Shi S, Du S, Zeng Z, et al. Treatment-duration is related to changes in peripheral lymphocyte counts during definitive radiotherapy for unresectable stage III NSCLC. Radiat Oncol. 2019;14:86.","journal-title":"Radiat Oncol"},{"key":"2791_CR18","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/978-3-319-62642-0_22","volume-title":"Handbook of Evidence-Based radiation oncology","author":"Y Yu","year":"2018","unstructured":"Yu Y, Anwar M, Chung HT. Colorectal cancer. In: Hansen EK, Roach Iii M, editors. Handbook of Evidence-Based radiation oncology. Cham: Springer International Publishing; 2018. pp. 491\u2013514."},{"key":"2791_CR19","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.ijrobp.2008.08.070","volume":"74","author":"RJ Myerson","year":"2009","unstructured":"Myerson RJ, Garofalo MC, El Naqa I, Abrams RA, Apte A, Bosch WR, et al. Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys. 2009;74:824\u201330.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2791_CR20","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1016\/j.ijrobp.2006.03.018","volume":"66","author":"LK Mell","year":"2006","unstructured":"Mell LK, Kochanski JD, Roeske JC, Haslam JJ, Mehta N, Yamada SD, et al. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66:1356\u201365.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2791_CR21","doi-asserted-by":"publisher","first-page":"778607","DOI":"10.3389\/fonc.2022.778607","volume":"12","author":"SJ Lee","year":"2022","unstructured":"Lee SJ, Kim K, Park HJ. Meta-Analysis on the Neutrophil-Lymphocyte ratio in rectal cancer treated with preoperative chemoradiotherapy: prognostic value of Pre- and Post-Chemoradiotherapy Neutrophil-Lymphocyte ratio. Front Oncol. 2022;12:778607.","journal-title":"Front Oncol"},{"key":"2791_CR22","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1038\/s12276-023-01105-x","volume":"55","author":"CH Koh","year":"2023","unstructured":"Koh CH, Lee S, Kwak M, Kim BS, Chung Y. CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential. Exp Mol Med. 2023;55:2287\u201399.","journal-title":"Exp Mol Med"},{"key":"2791_CR23","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991\u20138.","journal-title":"Nat Immunol"},{"key":"2791_CR24","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1158\/0008-5472.CAN-13-2084","volume":"74","author":"I Romero","year":"2014","unstructured":"Romero I, Garrido C, Algarra I, Collado A, Garrido F, Garcia-Lora AM. T lymphocytes restrain spontaneous metastases in permanent dormancy. Cancer Res. 2014;74:1958\u201368.","journal-title":"Cancer Res"},{"key":"2791_CR25","doi-asserted-by":"publisher","first-page":"101662","DOI":"10.1016\/j.adro.2024.101662","volume":"10","author":"B Huang","year":"2025","unstructured":"Huang B, Lv J, Xiong J, Peng F, Zhuo L, Yang Z, et al. The influence of pelvic bone Dose-volume parameters on bone marrow suppression during radiation therapy in patients with stage I to III rectal cancer based on Real-world data. Adv Radiat Oncol. 2025;10:101662.","journal-title":"Adv Radiat Oncol"},{"key":"2791_CR26","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13014-015-0454-0","volume":"10","author":"J Wan","year":"2015","unstructured":"Wan J, Liu K, Li K, Li G, Zhang Z. Can dosimetric parameters predict acute hematologic toxicity in rectal cancer patients treated with intensity-modulated pelvic radiotherapy? Radiat Oncol. 2015;10:162.","journal-title":"Radiat Oncol"},{"key":"2791_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.radonc.2014.09.002","volume":"113","author":"TJ Yang","year":"2014","unstructured":"Yang TJ, Oh JH, Apte A, Son CH, Deasy JO, Goodman KA. Clinical and dosimetric predictors of acute hematologic toxicity in rectal cancer patients undergoing chemoradiotherapy. Radiother Oncol. 2014;113:29\u201334.","journal-title":"Radiother Oncol"},{"key":"2791_CR28","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1088\/0031-9155\/5\/3\/302","volume":"5","author":"RE Ellis","year":"1961","unstructured":"Ellis RE. The distribution of active bone marrow in the adult. Phys Med Biol. 1961;5:255\u20138.","journal-title":"Phys Med Biol"},{"key":"2791_CR29","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.radonc.2022.10.019","volume":"177","author":"B Venkatesulu","year":"2022","unstructured":"Venkatesulu B, Giridhar P, Pujari L, Chou B, Lee JH, Block AM, et al. Lymphocyte sparing normal tissue effects in the clinic (LymphoTEC): A systematic review of dose constraint considerations to mitigate radiation-related lymphopenia in the era of immunotherapy. Radiother Oncol. 2022;177:81\u201394.","journal-title":"Radiother Oncol"},{"key":"2791_CR30","first-page":"437","volume":"40","author":"H Qing","year":"2019","unstructured":"Qing H, Chuanshu C, Weijian Z, Shaobin Z, Jing L. Low-dose range of pelvic irradiation leads to acute hematological toxicity in early-stage cervical cancer with intermediate risk factors by postoperative intensity-modulated radiotherapy. Eur J Gynaecol Oncol. 2019;40:437\u201342.","journal-title":"Eur J Gynaecol Oncol"},{"key":"2791_CR31","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1667\/RR15367.1","volume":"193","author":"SG Ellsworth","year":"2020","unstructured":"Ellsworth SG, Yalamanchali A, Zhang H, Grossman SA, Hobbs R, Jin JY. Comprehensive analysis of the kinetics of radiation-Induced lymphocyte loss in patients treated with external beam radiation therapy. Radiat Res. 2020;193:73\u201381.","journal-title":"Radiat Res"},{"key":"2791_CR32","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes A, Adam R, Rosello S, Arnold D, Normanno N, Taieb J, et al. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:10\u201332.","journal-title":"Ann Oncol"},{"key":"2791_CR33","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1007\/s00066-020-01659-z","volume":"196","author":"\u0141 Kuncman","year":"2020","unstructured":"Kuncman \u0141, Stawiski K, Mas\u0142owski M, Kucharz J, Fijuth J. Dose-volume parameters of MRI-based active bone marrow predict hematologic toxicity of chemoradiotherapy for rectal cancer. Strahlenther Onkol. 2020;196:998\u20131005.","journal-title":"Strahlenther Onkol"},{"key":"2791_CR34","doi-asserted-by":"publisher","first-page":"7566","DOI":"10.1038\/s41598-023-34145-4","volume":"13","author":"S Li","year":"2023","unstructured":"Li S, Yao W, Liu R, Lu Y, Zhang H, Liang X. Severe lymphopenia as a prognostic factor in rectal cancer patients receiving adjuvant chemoradiotherapy: a retrospective study. Sci Rep. 2023;13:7566.","journal-title":"Sci Rep"},{"key":"2791_CR35","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1748-717X-5-17","volume":"5","author":"L Arbea","year":"2010","unstructured":"Arbea L, Ramos LI, Martinez-Monge R, Moreno M, Aristu J. Intensity-modulated radiation therapy (IMRT) vs. 3D conformal radiotherapy (3DCRT) in locally advanced rectal cancer (LARC): dosimetric comparison and clinical implications. Radiat Oncol. 2010;5:17.","journal-title":"Radiat Oncol"},{"key":"2791_CR36","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.radonc.2015.11.020","volume":"118","author":"C Sini","year":"2016","unstructured":"Sini C, Fiorino C, Perna L, Noris Chiorda B, Deantoni CL, Bianchi M, et al. Dose-volume effects for pelvic bone marrow in predicting hematological toxicity in prostate cancer radiotherapy with pelvic node irradiation. Radiother Oncol. 2016;118:79\u201384.","journal-title":"Radiother Oncol"},{"key":"2791_CR37","first-page":"100562","volume":"39","author":"C Pedone","year":"2023","unstructured":"Pedone C, Sorcini B, Staff C, F\u00e4rlin J, Fokstuen T, Fr\u00f6din JE, et al. Preoperative short-course radiation therapy with protons compared to photons in high-risk rectal cancer (PRORECT): initial dosimetric experience. Clin Transl Radiat Oncol. 2023;39:100562.","journal-title":"Clin Transl Radiat Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-026-02791-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-026-02791-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-026-02791-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:21:09Z","timestamp":1781630469000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13014-026-02791-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2791"],"URL":"https:\/\/doi.org\/10.1186\/s13014-026-02791-3","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"assertion":[{"value":"20 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the ethical standards of the institutional and national research committees and with the 1964 Helsinki Declaration and its later amendments. The study protocol was approved by the Institutional Review Board of Tri-Service General Hospital (IRB No. B202505041). As this was a retrospective analysis of anonymized clinical data, the requirement for individual informed consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}